Defining Features of Rapid-Acting Therapies in MDD
Roger S. McIntyre, MD, FRCPC, discusses the history of psychiatry and the conventional treatment and response times, leading into the current treatment armamentarium for treatment of major depressive disorder (MDD).
Overview of Rapid-Acting Therapies in Major Depressive Disorder (MDD)
Carmen Kosicek, MSN, PMHNP-BC, reviews the definition of “rapid-acting” therapies as well as their role in treating major depressive disorder (MDD).
Chapter 8. Managing Patient Expectations During Treatment for ADHD
Sponsored by: Ironshore Pharmaceuticals
Chapter 6. Optimizing the Duration of Effect with Stimulant Medications
Chapter 5. Adult Perspectives on ADHD Medications
Chapter 4. Optimal Treatment Outcomes for Treating Patients With ADHD
Chapter 3. Pharmacokinetic Profiles of Long-Acting Stimulants
Chapter 2. Guidance and Recommendations for the use of Stimulants in Adults With ADHD
Chapter 1. History of Stimulants in ADHD
Practice Pearls for Optimizing MDD Treatment
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, provide their practice pearls for community psychiatrists and psychiatric nurse practitioners who care for patients with major depressive disorder (MDD) to optimize their treatment and management.
New Classes of Treatment for MDD
Experts provide an overview of novel treatments, including glutamatergic, GABAergic, and psychedelic drugs, that are either approved or currently being evaluated in clinical studies for MDD (major depressive disorders).
Treatment Switch for MDD
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss the typical strategies for switching therapies for major depressive disorder (MDD).
Practitioners discuss the need to treat patients with major depressive disorder (MDD) to a complete remission vs a decline in symptomology.
MDD Treatment: Follow-Up
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss best practices for monitoring and follow-up with patients with major depressive disorder (MDD) to ensure treatment efficacy and safety.
Approach to Treatment in Patients with MDD
Practitioners discuss their approach to treatment with their patients with major depressive disorder (MDD).
MDD as a Chronic Condition
Experts discuss how practitioners are viewing major depressive disorder (MDD) as a chronic condition vs an episodic condition.
Tailoring Treatments for Patients With MDD
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss navigating the challenge of a “one size fits all approach” when treating and identifying the specific needs of patients with major depressive disorder (MDD).
Undertreatment in Patients Suffering From MDD
Practitioners discuss the rates of undertreatment in patients suffering from major depressive disorder (MDD).
Healthcare Perception of Major Depressive Disorder
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, comment on the perception of major depressive disorder (MDD) within the healthcare community and the clinical and practical implications of is this condition.
Practice Pearls for Narcolepsy Management
Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, share take-home messages for the management of narcolepsy.
Case #2: 29-Year-Old Male With Type 2 Narcolepsy
Experts in sleep medicine present a case of a 29-year-old male with EDS, vivid dreams, sleep paralysis, and adult ADD, and share their initial impressions.
Case #1: 18-Year-Old Female With Type 1 Narcolepsy
Sleep experts present a case of an 18-year-old female preparing for college with EDS and cataplexy, and share their approach to treatment.
Unmet Needs in Narcolepsy Treatment
Drs Asim Roy and Richard K. Bogan discuss remaining unmet needs in the therapeutic landscape for narcolepsy.
Newer Agents for the Management of Narcolepsy
Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, comment on the evolving treatment landscape for narcolepsy and patient selection of FDA-approved agents: solriamfetol, pitolisant, and lower-sodium oxybate.
Therapeutic Options for the Management of Narcolepsy
Experts in sleep medicine share insight on initiating treatment for the management of narcolepsy.
Diagnosis of Narcolepsy and Impact on QoL
Sleep experts comment on diagnostic criteria for narcolepsy, factors that may lead to misdiagnosis, and the impact of the condition on a patient’s quality of life.
Overview and Triggers of Narcolepsy
Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, provide an overview of the pathophysiology of narcolepsy and the role of orexin in regulating the sleep/wakefulness cycle.
Key Takeaways for the Management of MDD
Carmen Kosicek, MSN, PMHNP-BC; Charles Montano, MD; and Gus Alva, MD, DFAPA, provide take-home messages for the management of patients with MDD and other depressive disorders.
Unmet Needs in MDD Treatment Paradigm
Experts in psychiatry examine emerging agents and unmet needs for the management of MDD.
Impact of Different MDD Classes of Treatment on Time to Response
Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, comment on the impact of various classes of MDD treatments on time to achieve goals and/or response.
2 Clarke Drive Cranbury, NJ 08512